BiotechTube

Risankizumab + Comparator

Pre-clinicalRecruiting
1 views this week 0 watching💤 Quiet
Interest: 33/100
33
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment

Conditions

Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment

Trial Timeline

Jul 30, 2021 → Jun 1, 2032

NCT ID
NCT04846959

About Risankizumab + Comparator

Risankizumab + Comparator is a pre-clinical stage product being developed by AbbVie for Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04846959. Target conditions include Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment.

What happened to similar drugs?

20 of 20 similar drugs in Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment were approved

Approved (20) Terminated (6) Active (0)
✅alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
✅alefaceptAstellas PharmaApproved
✅alefaceptAstellas PharmaApproved
✅AlefaceptAstellas PharmaApproved
✅Halobetasol Topical LotionSun PharmaceuticalApproved
✅Topicort® (desoximetasone) Topical Spray, 0.25%Sun PharmaceuticalApproved
✅KHK4827-Active + KHK4827-PlaceboKyowa KirinApproved

Hype Score Breakdown

Clinical
3
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04846959Pre-clinicalRecruiting

Competing Products

20 competing products in Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment

See all competitors
ProductCompanyStageHype Score
CT-P17 + EU-approved HumiraCelltrionPhase 3
40
CT-P55 + EU-approved CosentyxCelltrionPhase 3
44
alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
43
alefaceptAstellas PharmaPhase 3
40
Amevive exposureAstellas PharmaPre-clinical
18
alefacept + placeboAstellas PharmaPhase 3
40
alefaceptAstellas PharmaApproved
43
alefaceptAstellas PharmaApproved
35
AlefaceptAstellas PharmaApproved
43
Halobetasol PropionateSun PharmaceuticalPhase 2
27
Placebo + SCD-044_Low Dose (Dose 1) + SCD-044_Intermediate Dose (Dose 2) + SCD-044_High Dose (Dose 3)Sun PharmaceuticalPhase 2
35
DSXS + PlaceboSun PharmaceuticalPhase 3
40
DSXSSun PharmaceuticalPhase 2
35
DSXS topicalSun PharmaceuticalPhase 2
35
Halobetasol Topical LotionSun PharmaceuticalApproved
35
Tildrakizumab 200 mg + Tildrakizumab 100 mg + Matching PlaceboSun PharmaceuticalPhase 3
40
DSXS1411 + PlaceboSun PharmaceuticalPhase 2
35
Tildrakizumab + PlaceboSun PharmaceuticalPhase 3
40
Tildrakizumab 200 mg + Tildrakizumab 100 mg + Tildrakizumab Placebo + Etanercept Placebo + Etanercept 50 mgSun PharmaceuticalPhase 3
40
MK-3222 200 mg + MK-3222 100 mg + Placebo to MK-3222 + Placebo to Etanercept + Etanercept 50 mgSun PharmaceuticalPhase 3
32